Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in cognitive function compared with those who received darolutamide (Nubeqa), according to results from a phase II trial.

Click to read more.